Clinical trial

Determination of a Trough Serum Concentration of Ofloxacin Associated to Increase in Side Effects Frequency in Elderly Treated for Bone and Joint Infection

Name
PI2019_843_0018
Description
Ofloxacin is a gold standard antibiotic for the treatment of bone and joint infections due to sensible staphylococcus strains. However, in the elderly, inter-individual variability of the pharmacokinetics may reduce the efficacy or increase toxicity. The occurrence of ofloxacin side effects is likely to be increased in case of higher exposition. However, the serum concentration-toxicity relationship has not yet been determined. The purpose of this project is to assess the association between the residual serum concentration of ofloxacin at day 3 and the occurrence of at least one adverse effect attributable to ofloxacin, and determine a threshold toxicity concentration if this association exists.
Trial arms
Trial start
2020-06-02
Estimated PCD
2023-06-01
Trial end
2023-08-01
Status
Recruiting
Treatment
ofloxacin
ofloxacin treatment in patients with bone and joint infections
questionnaire
questionnaire of ofloxacine side effects will be completed by the clinician at Day 3, Day 21 and Day 42
Ofloxacin Serum concentration
Serum concentration of ofloxacin will be measured at Day 3 (Cmin and Cmax), Day 21 and Day 42 (Cmin).
Size
110
Primary endpoint
Frequency of one adverse reaction attributable to ofloxacin in patients with bone and joint infections
day 3
Eligibility criteria
Inclusion Criteria: * Patients aged over 65 years hospitalized at the University Hospital of Amiens for an uncomplicated bone and joint infections * Indication for oral switch to ofloxacin Exclusion Criteria: * Patient refusing to participate in the study * Patient under guardianship or curators or deprived of public rights * Any liver or biliary injury * Any contraindications to ofloxacin
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 110, 'type': 'ESTIMATED'}}
Updated at
2023-03-22

1 organization

2 products

4 indications

Product
ofloxacin
Indication
Ofloxacin
Product
Ofloxacin